Sign In
Buy TNXP
$12.20
+0.190 (+1.58%)
At Close: Jun 22, 2026
Tonix Pharmaceuticals Presents Vaccine Platform Data in Keynote Talk at the Vaccine Congress 2024
08:00am, Tuesday, 25'th Jun 2024
Tonix's live virus vaccine TNX-801 is designed to provide long-term protection from mpox and smallpox with one dose
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for June 2024
12:31pm, Tuesday, 18'th Jun 2024
As the main stock indices like the S&P 500 and Nasdaq continue to climb, penny stocks are becoming attractive for those seeking significant returns. Despite their reputation for extreme price fluctuat
Tonix Pharmaceuticals Announces Closing of $4.0 Million Public Offering
05:00pm, Thursday, 13'th Jun 2024
CHATHAM, N.J., June 13, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biopharmaceutical company, today announced th
Tonix Pharmaceuticals Announces Pricing of $4.0 Million Public Offering
09:00am, Wednesday, 12'th Jun 2024
CHATHAM, N.J., June 12, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biopharmaceutical company, today announced i
Why Is Tonix Pharmaceuticals (TNXP) Stock Down 40% Today?
08:52am, Wednesday, 12'th Jun 2024
Tonix Pharmaceuticals (NASDAQ: TNXP ) stock is falling on Wednesday after the biopharmaceutical company announced a proposed public offering for its shares. Tonix Pharmaceuticals doesn't provide any
Tonix Pharmaceuticals Announces Proposed Public Offering
05:17pm, Tuesday, 11'th Jun 2024
CHATHAM, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biopharmaceutical company, today announced
Why Is Tonix Pharmaceuticals (TNXP) Stock Down 31% Today?
11:55am, Monday, 10'th Jun 2024
Tonix Pharmaceuticals (NASDAQ: TNXP ) stock is falling hard on Monday after the company's shares underwent a reverse stock split this morning. That reverse stock split saw Tonix Pharmaceuticals consol
Tonix Pharmaceuticals Announces 1-for-32 Reverse Stock Split
11:00am, Thursday, 06'th Jun 2024
CHATHAM, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), fully-integrated biopharmaceutical company with marketed products and a pipe
Tonix Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
08:00am, Wednesday, 15'th May 2024
CHATHAM, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pip
Tonix Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Highlights
04:30pm, Monday, 13'th May 2024
On track to submit NDA in the second half of 2024 for Tonmya™ for fibromyalgia; pre-NDA meeting with FDA scheduled for second quarter 2024
Tonix Pharmaceuticals Announces Presentation at Planet MicroCap Showcase
08:00am, Wednesday, 24'th Apr 2024
CHATHAM, N.J., April 24, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of develo
3 Biotech Stocks to Dump Before They Go to Zero
06:31am, Tuesday, 09'th Apr 2024
It is not a bad idea to hunt for biotech stocks to sell. Such stocks have earned a bad reputation among investors, and for good reason.
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
04:15pm, Monday, 01'st Apr 2024
Positive results from confirmatory Phase 3 RESILIENT study reported in December 2023 position Tonmya™ for fibromyalgia for NDA submission second half of 2024; pre-NDA meeting with FDA scheduled for
Tonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct Offering
09:32am, Thursday, 28'th Mar 2024
CHATHAM, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a biopharmaceutical company, today announced it has entered in
TNX-2900 is a proprietary magnesium-potentiated formulation of intranasal oxytocin, a naturally occurring hormone that reduces appetite and eating
